Navigation Links
NeurogesX CEO Anthony DiTonno to Retire by Year End
Date:4/29/2011

y of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza and the timing of retirement and replacement of the Company's current President and Chief Executive Officer.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submissi
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
2. NeurogesX to Present at J.P. Morgan Health Care Conference
3. NeurogesX to Present at Piper Jaffray Health Care Conference
4. NeurogesX Reports Third Quarter 2009 Results
5. NeurogesX to Present at Two November Conferences
6. NeurogesX to Present at UBS Global Life Sciences Conference
7. NeurogesX to Present at Upcoming Fall Conferences
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. NeurogesX Reports Second Quarter 2009 Results
10. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
11. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Jan. 31, 2012  Argos Therapeutics Inc., today announced ... analysis of AGS-003-006, a Phase 2 study of ... in patients with advanced renal cell carcinoma (RCC). ... anti-tumor memory T cell responses and overall survival. ...
... 2012   Veracyte, Inc ., a molecular diagnostics company ... the appointment of Mark Spring as chief financial officer. ... has joined the Veracyte team," said Bonnie Anderson, Veracyte,s ... a CFO and senior finance leader in both public ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... the following upcoming investment conferences in February. ... present at the Leerink Swann 2012 Global Healthcare Conference ... Life Technologies will also present at the 2012 ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Life Technologies to Present at Upcoming Investment Conferences in February 2
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has been a well-kept secret of our immune system,s success. The ... Cell Press publication, offer an explanation for how specialized immune cells ... in the process. The focus of the study is a ... a pore in cells targeted for destruction. With that pore in ...
... uncovered a new role for a key cancer protein, a ... of a variety of tumors. Many cancers are driven ... the cells to escape growth controls and proliferate abnormally. In ... Nature , researchers discovered that cyclin D1 also helps ...
... Evidence from benchmark sites across the ... allows for land-use sharing in agriculture, forests and other ... gas emissions and raising food production levels. It provides ... land for forests through agricultural intensification. Agricultural intensification, also ...
Cached Biology News:How killer immune cells avoid killing themselves 2Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3Integrating agriculture and forestry in the landscape is key to REDD 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides) and PDMS Stamps (3 PDMS micropatterned stamps with ... um x 10 mm or 200 um x 10 ...
Biology Products: